Rhythm Pharmaceuticals (RYTM) Stock Forecast & Price Target

Rhythm Pharmaceuticals is positioned favorably because IMCIVREE continues to demonstrate clinically meaningful efficacy across multiple rare neuroendocrine indications, including a statistically significant -18.8% placebo-adjusted BMI reduction in the Phase 3 TRANSCEND trial in 142 patients with acquired hypothalamic obesity and sustained benefit in PWS where BMI improved from -1.84% at 3 months to -3.06% at 6 months. The Japan approval in late August 2026 adds a meaningful new commercial opportunity, with Rhythm estimating 5,000 to 8,000 people living with acquired HO in Japan and expecting launch before the end of 2026, which should extend revenue growth beyond the company’s dominant U.S. segment. Its pipeline further supports the outlook, as RM-718 showed an -11.6% mean BMI reduction at 16 weeks in Phase 2 with limited hyperpigmentation and bivamelagon-like efficacy, while broader improvements in hyperphagia, anxiety, body composition, and tolerability strengthen the case for durable adoption.

Rhythm Pharmaceuticals is facing a challenging commercialization profile because Imcivree only began active commercialization efforts in the US and EU in 2022, leaving open the risk that early launch execution may not generate meaningful uptake in the approved indications. Competitive pressure is also a major headwind, as approved GLP-1 therapies from large pharmaceutical companies could limit adoption of Imcivree in current and future uses, while clinical trials for setmelanotide may fail to replicate earlier safety or efficacy in later-stage or exploratory programs. The outlook is further weakened by patent and IP risk, since setmelanotide will face generic competition when patents expire, and granted patents could be challenged earlier than expected, undermining long-term exclusivity.